# Immunic links vidofludimus calcium to cognition gains and neuron protection

- URL: https://stocks.freetheai.org/news/immunic-links-vidofludimus-calcium-to-cognition-gains-and-neuron-protection-5cca57
- Published: 2026-10-12T11:00:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:IMUX](https://stocks.freetheai.org/symbols/NASDAQ-IMUX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Immunic, Inc. (NASDAQ:IMUX) reported post-hoc CALLIPER analysis linking vidofludimus calcium with reduced Epstein-Barr virus (EBV)-specific T-cell receptors and improved cognitive performance. The analysis also examined a bidirectional disability endpoint for future progressive multiple sclerosis trials.

Separate preclinical findings indicated that vidofludimus calcium promoted human neuron survival through Nurr1, reduced microglia-driven neuron loss in laboratory testing and improved disease markers in an MS model. The findings could help inform trial endpoints, although the cognition analysis was post-hoc and the neuron data were preclinical.

Immunic shares were recently at $8.19, up 8.33% on the day. Investors may next focus on how the company translates these findings into clinical trial design and whether later-stage data support the observed effects.

## Key points

- CALLIPER post-hoc analysis linked vidofludimus calcium to lower EBV-specific T-cell receptor levels.
- The analysis associated the reduction with improved cognition.
- Preclinical data showed neuron survival through Nurr1 activation.
- Vidofludimus calcium reduced microglia-driven neuron loss in vitro.
- Immunic shares were at $8.19, up 8.33% on the day.

## Questions and answers

### What did Immunic report about vidofludimus calcium and cognition?

A post-hoc CALLIPER analysis linked reduced EBV-specific T-cell receptors after treatment with improved cognitive performance.

### How could Immunic’s preclinical data affect future MS trials?

The findings may help inform trial endpoints after showing neuron survival via Nurr1, reduced microglia-driven neuron loss and improved MS model markers.